^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Colon Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

    Excerpt:
    ...Ras/Braf mutation analysis at enrollment identifies Ras/Braf status as either the wild type or mutant type....
    Trial ID:
    QUATTRO-II
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells

    Excerpt:
    ...Overall survival (OS)`Response rate (RR)`Radical Resection (R0) surgery rate`Circulating Tumour Cells (CTC) count basal and correlate to PFS, OS, RR`Correlation of RAS, BRAF and PI3K mutations and clinical anti-tumour activity outcome ( PFS, OS, RR)`Adverse events`Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)...
    Trial ID:
    VISNU-1
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Gan To Kagaku Ryoho
    Title:

    A Case of mFOLFOX6 + Bevacizumab Responding to Intraperitoneally Disseminated Nodule after Transverse Colon Cancer

    Excerpt:
    The case is a male in the 80s. Transverse colectomy was performed with the diagnosis of transverse colon cancer, and pT3, pN0, cM0, pStage IIa, RAS mutation negative, and BRAF mutation positive. One year and seven months after the operation, mFOLFOX6 + bevacizumab was started because of a recurrence of disseminated nodules in the abdominal cavity, and a total of 8 courses were performed...The disseminated nodules did not grow even after one year from the time when the disseminated nodules almost disappeared, and the patient is being followed up without treatment.